Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Asia Diagnostics Summit 2018

Max Ma's Biography

Max Ma, Director, Medical Affairs, Roche Sequencing Solutions, Inc.

Dr. Ma joined Roche in 2008 and held a number of positions with increasing responsibility in various business areas. He joined Genentech as an Oncology Biomarker Scientist discovering predictive biomarkers for various targeted therapies. In 2011, he moved to Roche Diagnostics as a team lead in Roche Molecular Diagnostics (RMD) developing oncology IVD assays. Early 2016, he joined Roche Sequencing Solutions (RSS), devoting his effort to building oncology sequencing assays and conducting clinical research after launching AVENIO assays globally. Max holds a PhD in Biochemistry from the University of Rochester, New York, followed by his postdoctoral training in Cancer Biology at Harvard Medical School. Dr. Max holds multiple patents on molecular technologies and publishes as a lead author in prestigious journals including EMBO, Nature Reviews and Cell.

Max Ma Image

Early Assessment of Treatment Response in Solid Tumors via Quantitating Circulating Tumor DNA

Monday, 5 November 2018 at 11:15

Add to Calendar ▼2018-11-05 11:15:002018-11-05 12:15:00Europe/LondonEarly Assessment of Treatment Response in Solid Tumors via Quantitating Circulating Tumor DNAAsia Diagnostics Summit 2018 in Taipei, TaiwanTaipei,

Thanks to the advancement of modern medicine, multiple therapeutic options often exist for the treatment of various cancers. Lessons learned from managing blood cancers under therapy have taught us the importance of early response. Longitudinal monitoring of circulating tumor DNA (ctDNA) is an emerging method for disease management in solid tumors. We employed a 197-gene NGS assay, the AVENIO ctDNA Surveillance Kit, which allowed us to perform longitudinal ctDNA analysis and measure changes in ctDNA levels in plasma. Specifically, we evaluated the association between change in ctDNA levels within first two cycles of treatment and survival data from a cohort of 106 advanced lung adenocarcinoma subjects treated with first-line chemo or chemoradiation therapies. Our data show that a decrease in post-treatment ctDNA level measured by the Surveillance Kit was associated with better outcome (both PFS and OS) in advanced lung adenocarcinoma. Thus, an early assessment of treatment effect can be measured using ctDNA in plasma within 1 or 2 treatment cycles.

Add to Calendar ▼2018-11-05 00:00:002018-11-06 00:00:00Europe/LondonAsia Diagnostics Summit 2018Asia Diagnostics Summit 2018 in Taipei, TaiwanTaipei,